Dr Mark Lythgoe
@drmarklythgoe.bsky.social
Medical Oncology fellow & Pharmacist at @imperialcollege @ImperialSandC doing PhD in #cancer #microbiome -interest in health policy, drug development & @rovers
Reposted by Dr Mark Lythgoe
Early-onset cancers (<50 yrs) are rising globally, linked to early-life exposures like diet, lifestyle, & microbiome changes. Awareness & dedicated studies are crucial. #Cancer #EarlyOnsetCancer #Oncology @oncoalert.bsky.social
rdcu.be/d49Ol
rdcu.be/d49Ol
December 30, 2024 at 11:28 AM
Early-onset cancers (<50 yrs) are rising globally, linked to early-life exposures like diet, lifestyle, & microbiome changes. Awareness & dedicated studies are crucial. #Cancer #EarlyOnsetCancer #Oncology @oncoalert.bsky.social
rdcu.be/d49Ol
rdcu.be/d49Ol
#Subcutaneous nivolumab approved by
@fda.gov across all indications - follows approval of SC atezolizumab in Sept 2024.
Will this be the preferred route of administration or will this suppress the development of new biosimilars?
@oncodaily.bsky.social @hemoncwarner.bsky.social
@fda.gov across all indications - follows approval of SC atezolizumab in Sept 2024.
Will this be the preferred route of administration or will this suppress the development of new biosimilars?
@oncodaily.bsky.social @hemoncwarner.bsky.social
December 29, 2024 at 2:49 PM
#Subcutaneous nivolumab approved by
@fda.gov across all indications - follows approval of SC atezolizumab in Sept 2024.
Will this be the preferred route of administration or will this suppress the development of new biosimilars?
@oncodaily.bsky.social @hemoncwarner.bsky.social
@fda.gov across all indications - follows approval of SC atezolizumab in Sept 2024.
Will this be the preferred route of administration or will this suppress the development of new biosimilars?
@oncodaily.bsky.social @hemoncwarner.bsky.social
Reposted by Dr Mark Lythgoe
Scientists, academics, researchers: We’re excited to share that @altmetric.com is now tracking mentions of your research on Bluesky! 🧪
There are already many articles for which there is more attention on Bluesky than on other comparable micro-blogging sites, meaning the academic community and the general public have clearly adopted Bluesky as one of its core places to disseminate and discuss new research.
A Place of Joy.
A Place of Joy.
December 3, 2024 at 2:10 PM
Scientists, academics, researchers: We’re excited to share that @altmetric.com is now tracking mentions of your research on Bluesky! 🧪
Wow #bluesky added to #altrimetric scores!
December 4, 2024 at 8:03 PM
Wow #bluesky added to #altrimetric scores!
Hugely interesting paper in
#nature
about #SONIA trial challenging frontline CDK4/6 use in #breastcancer - does this have implications for practice today?
www.nature.com/articles/s41...
#nature
about #SONIA trial challenging frontline CDK4/6 use in #breastcancer - does this have implications for practice today?
www.nature.com/articles/s41...
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature
The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
www.nature.com
November 27, 2024 at 10:26 PM
Hugely interesting paper in
#nature
about #SONIA trial challenging frontline CDK4/6 use in #breastcancer - does this have implications for practice today?
www.nature.com/articles/s41...
#nature
about #SONIA trial challenging frontline CDK4/6 use in #breastcancer - does this have implications for practice today?
www.nature.com/articles/s41...
Reposted by Dr Mark Lythgoe
How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice ascopubs.org/doi/10.1200/... #LCSM
How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice
Until the early 2000s, advanced or metastatic non–small cell lung cancer (NSCLC) was
treated as a single disease with all histologic subtypes treated alike with standard
chemotherapy agents. Over the ...
ascopubs.org
November 18, 2024 at 12:38 PM
How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice ascopubs.org/doi/10.1200/... #LCSM
Reposted by Dr Mark Lythgoe
The World Health Organization notes 300 essential drugs are now in shortage.
What's behind the problems and what are countries doing about it?
www.bmj.com/content/387/...
What's behind the problems and what are countries doing about it?
www.bmj.com/content/387/...
November 15, 2024 at 5:37 PM
The World Health Organization notes 300 essential drugs are now in shortage.
What's behind the problems and what are countries doing about it?
www.bmj.com/content/387/...
What's behind the problems and what are countries doing about it?
www.bmj.com/content/387/...